1013 related articles for article (PubMed ID: 19937839)
1. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
Reichel A
Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
[TBL] [Abstract][Full Text] [Related]
2. Strategies to optimize brain penetration in drug discovery.
Liu X; Chen C
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):505-12. PubMed ID: 16022187
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the blood-brain barrier in CNS drug discovery.
Jeffrey P; Summerfield S
Neurobiol Dis; 2010 Jan; 37(1):33-7. PubMed ID: 19664709
[TBL] [Abstract][Full Text] [Related]
4. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
5. Challenges for blood-brain barrier (BBB) screening.
Jeffrey P; Summerfield SG
Xenobiotica; 2007; 37(10-11):1135-51. PubMed ID: 17968740
[TBL] [Abstract][Full Text] [Related]
6. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system.
Fridén M; Ducrozet F; Middleton B; Antonsson M; Bredberg U; Hammarlund-Udenaes M
Drug Metab Dispos; 2009 Jun; 37(6):1226-33. PubMed ID: 19299522
[TBL] [Abstract][Full Text] [Related]
8. Assessing brain free fraction in early drug discovery.
Read KD; Braggio S
Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):337-44. PubMed ID: 20102287
[TBL] [Abstract][Full Text] [Related]
9. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system distribution kinetics of indinavir in rats.
Hamidi M
J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
[TBL] [Abstract][Full Text] [Related]
12. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
Shen DD; Artru AA; Adkison KK
Adv Drug Deliv Rev; 2004 Oct; 56(12):1825-57. PubMed ID: 15381336
[TBL] [Abstract][Full Text] [Related]
13. Mitigating permeability-mediated risks in drug discovery.
Wang J; Skolnik S
Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in physicochemical and ADMET profiling in drug discovery.
Wang J; Skolnik S
Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
[TBL] [Abstract][Full Text] [Related]
15. Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Wan H; Ahman M; Holmén AG
J Med Chem; 2009 Mar; 52(6):1693-700. PubMed ID: 19256501
[TBL] [Abstract][Full Text] [Related]
16. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
17. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
J Pharmacol Exp Ther; 2005 Jun; 313(3):1254-62. PubMed ID: 15743928
[TBL] [Abstract][Full Text] [Related]
18. Current in vitro and in silico models of blood-brain barrier penetration: a practical view.
Vastag M; Keseru GM
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):115-24. PubMed ID: 19152220
[TBL] [Abstract][Full Text] [Related]
19. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
20. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind".
Goodwin JT; Clark DE
J Pharmacol Exp Ther; 2005 Nov; 315(2):477-83. PubMed ID: 15919767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
